259 related articles for article (PubMed ID: 34597729)
1. Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.
Schwartz DA; Peyrin-Biroulet L; Lasch K; Adsul S; Danese S
Clin Gastroenterol Hepatol; 2022 May; 20(5):1059-1067.e9. PubMed ID: 34597729
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
Feagan BG; Schwartz D; Danese S; Rubin DT; Lissoos TW; Xu J; Lasch K
J Crohns Colitis; 2018 Apr; 12(5):621-626. PubMed ID: 29471381
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2.
Ruemmele FM; Rosh J; Faubion WA; Dubinsky MC; Turner D; Lazar A; Eichner S; Maa JF; Alperovich G; Robinson AM; Hyams JS
J Crohns Colitis; 2018 Nov; 12(10):1249-1254. PubMed ID: 29939254
[TBL] [Abstract][Full Text] [Related]
4. Clinical and magnetic resonance imaging spectrum of complex perianal fistulizing Crohn's disease: A cohort study from northern India.
Singh A; Kakkar C; Garg S; Arora K; Midha V; Mahajan R; Virk SS; Jain NP; Singh D; Sood K; Tripathi A; Gupta D; Kaushal IG; Galhotra RD; Saggar K; Sood A
Indian J Gastroenterol; 2023 Oct; 42(5):668-676. PubMed ID: 37548863
[TBL] [Abstract][Full Text] [Related]
5. Clinical and MRI Evolution After Local Injection of Bone Marrow-Derived Mesenchymal Stem Cells in Perianal Fistulae in Crohn's Disease: Results From a Prospective Monocentric Study.
Reenaers C; Gillard RP; Coimbra C; Gillard RM; Meunier P; Lechanteur C; Baudoux E; Boutaffala L; Beguin Y; Louis É
J Crohns Colitis; 2023 May; 17(5):728-737. PubMed ID: 36733215
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn's disease in Europe: a retrospective observational study.
Weisshof R; Vavricka SR; Pouillon L; Braegger F; Roset M; Bent-Ennakhil N; Ferrante M
BMC Gastroenterol; 2023 Nov; 23(1):417. PubMed ID: 38030966
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
8. AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study.
Reinisch W; Travis S; Hanauer S; Wang H; Shara N; Harris MS
Inflamm Bowel Dis; 2014 May; 20(5):872-81. PubMed ID: 24694794
[TBL] [Abstract][Full Text] [Related]
9. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome.
Ardizzone S; Maconi G; Colombo E; Manzionna G; Bollani S; Bianchi Porro G
Inflamm Bowel Dis; 2004 Mar; 10(2):91-6. PubMed ID: 15168807
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
Vermeire S; D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Bhatia S; Agboton C; Rosario M; Chen C; Zhang W; Kisfalvi K; Sandborn WJ
J Crohns Colitis; 2022 Jan; 16(1):27-38. PubMed ID: 34402887
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.
Zhu M; Xu X; Feng Q; Cui Z; Wang T; Yan Y; Ran Z
Dig Dis Sci; 2021 May; 66(5):1658-1668. PubMed ID: 32524415
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients.
Chapuis-Biron C; Bourrier A; Nachury M; Nancey S; Bouhnik Y; Serrero M; Armengol-Debeir L; Buisson A; Tran-Minh ML; Zallot C; Fumery M; Bouguen G; Abitbol V; Viennot S; Chanteloup E; Rajca S; Dib N; Parmentier AL; Peyrin-Biroulet L; Vuitton L;
Aliment Pharmacol Ther; 2020 Apr; 51(7):719-727. PubMed ID: 32080886
[TBL] [Abstract][Full Text] [Related]
15. Use of Endoscopic Ultrasound to Guide Adalimumab Treatment in Perianal Crohn's Disease Results in Faster Fistula Healing.
Wiese DM; Beaulieu D; Slaughter JC; Horst S; Wagnon J; Duley C; Annis K; Nohl A; Herline A; Muldoon R; Geiger T; Wise PE; Schwartz DA
Inflamm Bowel Dis; 2015 Jul; 21(7):1594-9. PubMed ID: 25985245
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn's Disease.
Swaroop S; Vuyyuru SK; Kante B; Kumar P; Mundhra SK; Arora U; Goyal A; Kandasamy D; Sharma R; Kabilan K; Kedia S; Dash NR; Ahuja V
Stem Cell Res Ther; 2024 May; 15(1):140. PubMed ID: 38745184
[TBL] [Abstract][Full Text] [Related]
17. Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn's Disease Patients.
van Rijn KL; Meima-van Praag EM; Bossuyt PM; D'Haens GR; Gecse KB; Horsthuis K; Snijder HJ; Tielbeek JAW; Buskens CJ; Stoker J
J Crohns Colitis; 2022 Jun; 16(5):708-716. PubMed ID: 34644395
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
Löwenberg M; Vermeire S; Mostafavi N; Hoentjen F; Franchimont D; Bossuyt P; Hindryckx P; Rispens T; de Vries A; van der Woude CJ; Berends S; Ambarus CA; Mathot R; Clasquin E; Baert F; D'Haens G
Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.
Newman KL; Johnson LA; Stidham RW; Higgins PDR
Therap Adv Gastroenterol; 2023; 16():17562848221148254. PubMed ID: 36895282
[TBL] [Abstract][Full Text] [Related]
20. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
